心力衰竭：我们治疗的对象与我们研究的对象。

Heart failure: who we treat versus who we study.

作者信息

Miller Leslie W

机构信息

Washington Hospital Center and Georgetown University, 110 Irving Street NW, 1E-7, Washington, DC 20010, USA.

出版信息

Cardiol Clin. 2008 Feb;26(1):113-25, viii. doi: 10.1016/j.ccl.2007.10.005.

DOI:10.1016/j.ccl.2007.10.005

PMID:18312911

Abstract

The prevalence of patients with the diagnosis of heart failure continues to increase, with recent data suggesting that the current estimate in the United States should now be over 7 million patients. There are many sources of information about the patients with heart failure. Many patients have been enrolled in pharmaceutical and devices trials in heart failure, but the patients enrolled are often not reflective of the patients being managed outside of these trials in terms of age, gender, race, and comorbidities. And yet, investigators have extrapolated the results of these trials to all patients with heart failure. This article offers a comparison of the demographics and outcomes of the patients with heart failure that investigators treat and those studied.

摘要

心力衰竭患者的患病率持续上升，最近的数据表明，目前美国的估计数应超过700万患者。关于心力衰竭患者有许多信息来源。许多患者已参加心力衰竭的药物和器械试验，但就年龄、性别、种族和合并症而言，入组的患者往往不能反映这些试验之外接受治疗的患者情况。然而，研究人员已将这些试验的结果外推至所有心力衰竭患者。本文比较了研究人员治疗的心力衰竭患者与所研究患者的人口统计学特征和结局。